The Pharma Data

NOVEMBER 11, 2020

McChesney is the founder and chief executive officer of Cloaked Therapeutics and Arbor Therapeutics, through which he has drawn on more than five decades of research in natural products chemistry to identify and develop novel cancer treatments. In 2009, he established Ironstone Separations Inc.,

Organic Chemistry 52

Organic Chemistry Science Pharmacy Pharmaceuticals 52

The Pharma Data

JULY 22, 2021

NOTE: ADUHELM TM (aducanumab-avwa)injection 100 mg/mL solutionis indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Biogen Inc.

Disease 52

Disease Research Clinical Trials FDA 52

Agency IQ

SEPTEMBER 15, 2023

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. The trials assessed change in nasal congestion score over one week of treatment. Both trials showed no difference between phenylephrine and placebo.

Science 40

Science FDA Clinical Trials Pharmacy 40

The Pharma Data

MAY 13, 2021

What I learned on the DVDs was the missing link when it comes to evaluation and eventual treatment of my clients planning for patients with muscular dysfunctions.”. ll see, and treatment strategies from some top notch names in our industry: Mike Robertson, Bill Hartman, Eric Beard, Rick Kaselj, Kevin Yates, and Dean Somerset.”.

Production 52

Production Treatment Vaccine Research 52

Drug & Device Law

MAY 30, 2022

The law presumes that licensed doctors know what they are doing. 1978), where a hypertensive patient was injured after being injected with the defendant’s drug – despite warnings that “expressly directed the doctor administering the drug to refrain from giving it to a patient with hypertension.” at *3 (emphasis original).

Testimonials 59

Testimonials Doctors Production Laboratories 59

Drug & Device Law

DECEMBER 11, 2023

May 28, 2015)); here (discussing In re Yasmin & Yaz (Drospirenone) Marketing, Sales Practices & Products Liability Litigation , 2011 WL 2746086 (S.D. Defendant] does not deny that it, the doctor, and the hospital are potential joint tortfeasors. . . . 2003 WL 27423681, at *4 (N.D. 2003 WL 27423679, at *3 (N.D.

Production 102

Production Hospitals Pharmaceuticals Doctors 102